• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

United delays Remosynch launch until 2018

April 3, 2017 By Sarah Faulkner

Medtronic's infusion pump problems delay United's Remosynch launch until 2018Shares in United Therapeutics (NSDQ:UTHR) fell -7% this morning to $126.17 apiece after the company said that the U.S. commercial launch of Remosynch, Medtronic‘s (NYSE:MDT) implantable infusion pump for Remodulin, will be delayed until 2018.

“United Therapeutics’ commitment to bringing better therapies to patients transcends temporary delays or setbacks,” United chairman & CEO Martine Rothblatt said in prepared remarks. “We are sorry to have missed our 2017 launch target, but it is a small miss in the context of our providing more U.S. pulmonary arterial hypertension patients with helpful medicines than any other company.”

A spokesperson for Medtronic said that Remosynch’s delayed launch and the recall for Medtronic’s SynchroMed pump are not related. The spokesperson cited “complexities related to the parallel [regulatory] filings” as the reason for delaying the product’s launch, not the recall.*

Analysts are concerned that any delay in debuting an alternative delivery option for Remodulin will make it harder for United to protect its sales as it faces generic competition in the year ahead.

The FDA rejected Medtronic’s marketing application for a Remodulin drug pump last year.

In March, the FDA updated Medtronic’s Class I recall for the company’s SynchroMed II and EL implantable drug pumps over a priming bolus issue. which Medtronic said it can fix with a software update.

*  Correction, April. 4, 2017: Updated April 4 to clarify that the delayed launch is not connected to Medtronic’s recall, according to a Medtronic spokesperson.↩

Filed Under: Drug-Device Combinations, Featured, Food & Drug Administration (FDA), Wall Street Beat Tagged With: Medtronic, United Therapeutics

IN CASE YOU MISSED IT

  • Elixir Medical reports sustained durability with bioadaptor compared to Medtronic stent
  • Senseonics closes public offering, private placement with Abbott
  • Embecta eyes shift from insulin delivery to broader medical supplies focus
  • Medtronic earns expanded CE mark for Prevail paclitaxel-coated balloon
  • Sequel Med Tech to pair automated insulin delivery system with Abbott’s future dual glucose-ketone sensor

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS